27 Recruiting Multiple Myeloma Clinical Trials in Arizona
Explore active multiple myeloma research studies enrolling across Arizona. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Multiple Myeloma Studies in Arizona
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
📍 City of Hope — Goodyear, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
📍 Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
📍 Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Arizona /ID# 260799 — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
📍 HonorHealth Cancer Transplant Institute — Scottsdale, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
📍 Banner Gateway Medical Center — Gilbert, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
📍 The University of Arizona Cancer Center — Tucson, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Yuma, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Phoenix — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
📍 Research Site — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
📍 Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
📍 Mayo Clinic Hospital Scottsdale /ID# 278349 — Scottsdale, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
📍 GSK Investigational Site — Bullhead City, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Arizona /ID# 251405 — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase4 💊 Investigational Drug / Biologic
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
📍 Mayo Clinic Cancer Center-Scottsdale — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
📍 Arizona Oncology Associates — Tucson, Arizona
View Study & Checklist ➔